VIDEO: Aflibercept 8 mg provides extended dosing intervals, visual benefits in DME
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Diana Do, MD, discusses the PHOTON extension study, which examined the effect of Eylea HD in patients with diabetic macular edema.
Do said patients treated with Eylea HD (aflibercept 8 mg, Regeneron) who achieved vision and anatomic gains in the first 2 years of the PHOTON trial were able to maintain their improvements in the extension study.
“The PHOTON data gives physicians more information about 8 mg of aflibercept for diabetic macular edema, showing that it can provide extended dosing intervals while maintaining those great benefits in visual acuity and reductions in diabetic macular edema,” Do said.
Collapse
Do D. Aflibercept 8 mg in DME: Key results from the PHOTON extension study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Read more about
Click Here to Manage Email Alerts